ライフサイエンスコーパス: ceftriaxone

1 SBL phenotype (based on nonsusceptibility to ceftriaxone).

2 lation (120 assigned to gatifloxacin, 119 to ceftriaxone).

3 gs: cefixime, chloramphenicol, ofloxacin, or ceftriaxone.

4 r bactericidal effect on S. epidermidis than ceftriaxone.

5 ceftriaxone, and Haemophilus influenzae and ceftriaxone.

6 influenzae in combination with cefotaxime or ceftriaxone.

7 ter one day of treatment with the antibiotic ceftriaxone.

8 fully subcultured by day 3 after exposure to ceftriaxone.

9 the antibiotics imipenem, penicillin G, and ceftriaxone.

10 cortex (mPFC) were quantified in response to ceftriaxone.

11 d decreased susceptibility to penicillin and ceftriaxone.

12 chloramphinicol, amoxicillin-clavulanate and ceftriaxone.

13 with single doses of ofloxacin, cefixime, or ceftriaxone.

14 rom cattle, all of which were susceptible to ceftriaxone.

15 tes from cattle, which was also resistant to ceftriaxone.

16 cefotaxime and 114 of 138 as susceptible to ceftriaxone.

17 ephalopathy can be treated successfully with ceftriaxone.

18 were reversed by the beta-lactam antibiotic ceftriaxone.

19 lin-resistant isolate, increased the MICs of ceftriaxone (0.4 mug/mL) and cefixime (1.2 mug/mL) to le

20 day for 14 days (with or without intravenous ceftriaxone, 1 g) (n = 127 included in the analysis).

21 Ceftriaxone 100 mg/kg per injection twice per day (200 m

22 no difference in mortality with intravenous ceftriaxone (121 of 230 patients) as compared with intra

23 230 patients) as compared with intramuscular ceftriaxone (128 of 229 patients) (odds ratio, 0.88; 95%

24 amil 600 mg given every 12 h was superior to ceftriaxone 2 g given every 24 h for the treatment of As

25 s ceftaroline fosamil (600 mg every 12 h) or ceftriaxone (2 g every 24 h) for 5-7 days.

26 articipants were randomly allocated (2:1) to ceftriaxone (2 g or 4 g per day) or placebo.

27 el trial of intramuscular versus intravenous ceftriaxone (2 g twice daily for 10 days) in adults with

28 The patients received either intravenous ceftriaxone, 2 g daily for 30 days, followed by oral dox

29 The efficacy of intravenous ceftriaxone, 2 g per day for 30 days, was evaluated in a

30 Treatment with ceftriaxone (200 mg/kg, i.p.) upregulated core GLT1 expr

31 Ceftriaxone (200 mg/kg, IP) was administered (vs. saline

32 or placebo (232 patients) plus intramuscular ceftriaxone (230 patients) or intravenous ceftriaxone (2

33 ar ceftriaxone (230 patients) or intravenous ceftriaxone (235 patients).

34 amoxicillin-clavulanate and 3 injections of ceftriaxone; 3 had recurrent AOM; and for 2 others, the

35 ion) increased survival in mice treated with ceftriaxone (5 days) from 40% to 100%.

36 nol for 48 h during which time they received ceftriaxone (50 or 100 mg/kg, IP) or saline twice a day

37 ycin, 96% were susceptible to penicillin and ceftriaxone, 54% were susceptible to ciprofloxacin, and

38 tifloxacin (10 mg/kg per day) or intravenous ceftriaxone (60 mg/kg up to 2 g per day for patients age

39 f 9,863 nonmeningeal isolates tested against ceftriaxone, 82.7% were susceptible, 13.2% were intermed

40 ncomycin (1103, 14.4%; 95% CI, 13.7%-15.2%), ceftriaxone (825, 10.8%; 95% CI, 10.1%-11.5%), piperacil

41 ts provided evidence that the combination of ceftriaxone (a cephalosporin antibiotic) and lansoprazol

42 del of ethanol withdrawal, we tested whether ceftriaxone, a beta-lactam antibiotic known to increase

43 lace preference (CPP), we determined whether ceftriaxone, a beta-lactam antibiotic known to increase

44 ne self-administration, while treatment with ceftriaxone, a beta-lactam antibiotic previously shown t

45 Other studies report that ceftriaxone, a glutamate transporter subtype-1 activator

46 nt of CDI in hospitalized patients receiving ceftriaxone, a high-risk antibiotic for CDI.

47 are the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) com

48 y; those with the highest rate had increased ceftriaxone administration and culturable Aspergillus, a

49 orin and azithromycin and those treated with ceftriaxone alone (9.1%; RR, 0.81; 95% CI, .18-3.60) or

50 liary side-effects, participants assigned to ceftriaxone also received 300 mg ursodeoxycholic acid tw

51 Ceftriaxone also reversed the cocaine-induced synaptic p

52 ipenem, filamentous cells with cefoxitin and ceftriaxone), amikacin and phages did not modify cell sh

53 Ceftriaxone, an antibiotic compound known to increase EA

54 Ceftriaxone, an expanded-spectrum cephalosporin, is an a

55 340 participants were randomly allocated to ceftriaxone and 173 to placebo.

56 it 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the

57 Of those patients, 74 (60%) received ceftriaxone and 50 (40%) received oxacillin.

58 ct roles for xCT and GLT-1 in the actions of ceftriaxone and add to a body of literature finding evid

59 to defervescence in 17 patients treated with ceftriaxone and azithromycin combination was 3.2 days (+

60 (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonorrhea to ensure eff

61 at day 14; among the 190 isolates with lower ceftriaxone and azithromycin MICs, only 13 (7%) had pers

62 Persistence was associated with elevated ceftriaxone and azithromycin MICs.

63 ntly more likely to exhibit elevated MICs of ceftriaxone and azithromycin than isolates from MSW (P <

64 as the undefined mechanisms of resistance to ceftriaxone and azithromycin underscore the importance o

65 ssed include whether to change the dosage of ceftriaxone and azithromycin used in the recommended dua

66 taphylococcus aureus strains were exposed to ceftriaxone and cefazolin at concentrations from 0 to 10

67 (and ESBL nonproducers) were susceptible to ceftriaxone and cefepime at the standard inoculum as wer

68 mutants to extended spectrum cephalosporins (ceftriaxone and cefepime) identified either PbpF or PonA

69 ance to the expanded-spectrum cephalosporins ceftriaxone and cefixime in Neisseria gonorrhoeae.

70 penA alleles on decreased susceptibility to ceftriaxone and cefixime, with the expectation that this

71 parate S. pneumoniae isolates susceptible to ceftriaxone and cefotaxime from those that are not susce

72 Overall, the new M100-S12 ceftriaxone and cefotaxime interpretative breakpoints fo

73 M100-S12 document in January 2002 introduced ceftriaxone and cefotaxime MIC interpretative breakpoint

74 usceptibility of Streptococcus pneumoniae to ceftriaxone and cefotaxime.

75 sceptible to failing cephalosporins, such as Ceftriaxone and Cefotaxime.

76 Ceftriaxone and cefotetan, which lack antienterococcal a

77 lates were susceptible by routine testing to ceftriaxone and ceftazidime, respectively.

78 g resistance to tetracycline, norfloxacylin, ceftriaxone and ciprofloxacin were observed among Gram n

79 nt recommend dual therapy with intramuscular ceftriaxone and either azithromycin or doxycycline.

80 the EHR, we found that patients taking both ceftriaxone and lansoprazole had significantly longer QT

81 Combination therapy of ceftriaxone and lansoprazole is associated with increase

82 agnosis, surgical admission, and duration of ceftriaxone and other antibiotics, for each day of doxyc

83 We compared ceftriaxone and piperacillin-tazobactam at doses ranging

84 and reduced susceptibility to penicillin and ceftriaxone and still predominated among declining serot

85 eriod at week 14, after the 2-week course of ceftriaxone and the 12-week course of the randomized stu

86 Resistance to ceftriaxone and the fluoroquinolones, which are used to

87 kpoints (2 each for aztreonam, cefepime, and ceftriaxone, and 1 for cefazolin and ceftazidime).

88 ross species, particularly to penicillin and ceftriaxone, and across geographical regions.

89 ad negative skin test results to cefuroxime, ceftriaxone, and aztreonam and tolerated challenges.

90 activity between penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects with T cell-m

91 e subjects could be treated with cefuroxime, ceftriaxone, and aztreonam.

92 ephalexin, cefaclor, cefadroxil, cefuroxime, ceftriaxone, and aztreonam.

93 ibitory concentrations (MICs) of penicillin, ceftriaxone, and cefixime for a wild-type strain (FA19)

94 icillin-clavulanic acid, cefdinir, cefixime, ceftriaxone, and clarithromycin were the most reproducib

95 r-Kelly medium in the presence or absence of ceftriaxone, and cultures were monitored for up to 56 da

96 , and gentamicin, Neisseria meningitidis and ceftriaxone, and Haemophilus influenzae and ceftriaxone.

97 of various antibiotics (i.e., ciprofloxacin, ceftriaxone, and tetracycline) against Escherichia coli

98 8 patients received prophylactic intravenous ceftriaxone (antibiotic group) and 147 patients did not

99 Our data suggest that ciprofloxacin and ceftriaxone are appropriate empirical therapy for suspec

100 Generic formulations of ceftriaxone are becoming more affordable and available,

101 Long-term treatment with ceftriaxone attenuates the reinstatement of cocaine seek

102 expression in the NAc.SIGNIFICANCE STATEMENT Ceftriaxone attenuates the reinstatement of cocaine, alc

103 Combination Ceftriaxone-Azithromycin therapy may provide a therapeut

104 ast 12 months (96%), and were treated with a ceftriaxone-based regimen (95%).

105 alosporin and azithromycin was comparable to ceftriaxone-based regimens in the treatment of pharyngea

106 Ceftriaxone blocked methamphetamine-triggered reinstatem

107 ehicle, whereas 100 or 200, but not 50 mg/kg ceftriaxone blocked this response.

108 ll) inputs or treatment with the antibiotic, ceftriaxone, blocked reinstatement of morphine-evoked co

109 n was specific to lansoprazole combined with ceftriaxone but not with other cephalosporins.

110 es (sensitivity 98% for cefixime and 91% for ceftriaxone), but alternative resistance mechanisms have

111 were intermediate, and 21 were resistant to ceftriaxone by MIC testing.

112 losporins, such as cefepime, cefotaxime, and ceftriaxone, by 9.1 to 13.0%, bringing their in vitro ra

113 of ciprofloxacin (A), azithromycin (B), and ceftriaxone (C).

114 Ceftriaxone can be dosed once daily and is less expensiv

115 mate transporter GLT-1 (N-acetylcysteine and ceftriaxone) can decrease measures of drug seeking.

116 underwent challenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibuten; and group C and

117 B was studied in combination with cefazolin, ceftriaxone, cefepime, imipenem, gentamicin, tigecycline

118 to effectively remove vancomycin, cefoxitin, ceftriaxone, cefepime, piperacillin-tazobactam, ampicill

119 determine antimicrobial susceptibilities of ceftriaxone, cefixime, and cefpodoxime in Neisseria gono

120 mine the susceptibility of N. gonorrhoeae to ceftriaxone, cefixime, and cefpodoxime, although we reco

121 % within 1 log2 dilution from each other for ceftriaxone, cefixime, and cefpodoxime, respectively.

122 lation coefficients of 92%, 91%, and 92% for ceftriaxone, cefixime, and cefpodoxime, respectively.

123 agreements were 99.1%, 98.3%, and 94.8% for ceftriaxone, cefixime, and cefpodoxime, respectively.

124 Isolates with decreased susceptibility to ceftriaxone, cefixime, azithromycin, and spectinomycin r

125 of 264 isolates were subjected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepime, and aztr

126 hoxazole and had reduced susceptibilities to ceftriaxone, cefotaxime, minocycline, and ciprofloxacin.

127 which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MRSA in

128 g an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated w

129 group A, positive responses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizim

130 or more of the following agents: ampicillin, ceftriaxone, ciprofloxacin, gentamicin, and/or trimethop

131 alone (9.1%; RR, 0.81; 95% CI, .18-3.60) or ceftriaxone combined with azithromycin or doxycycline (1

132 e tested against cefepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY)

133 However, ceftriaxone did not reverse stress-induced synaptic pote

134 d immunoprecipitation of GLT-1 revealed that ceftriaxone does not upregulate GLT-1 and xCT through a

135 In this cohort of patients receiving ceftriaxone, doxycycline was associated with lower risk

136 tes had low MICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linezolid, meropenem, penicill

137 ice treated with the beta-lactam antibiotic, ceftriaxone, during cocaine withdrawal.

138 Ceftriaxone elevated EAAT2 transcription in PHFA through

139 Salmonella group B resistant to ceftriaxone emerged in 2009 and 2010 (6.2% [2/32 isolate

140 We investigated the mechanism by which ceftriaxone enhances EAAT2 expression in primary human f

141 In separate groups of rats, 200 mg/kg ceftriaxone failed to block cue-induced food seeking, ar

142 Ceftriaxone failed to promote colonization at doses up t

143 istration were treated with the same dose of ceftriaxone followed by intracore or intrashell infusion

144 study groups received open-label intravenous ceftriaxone for 2 weeks before initiating the randomized

145 e aimed to assess the safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis in a combi

146 ot inferior to intravenous administration of ceftriaxone for bacterial meningitis.

147 to be noninferior to the comparator agents (ceftriaxone for CABP and vancomycin plus aztreonam for A

148 Intra-NAc xCT knockdown prevented ceftriaxone from attenuating reinstatement and from upre

149 Intra-NAc GLT-1 knockdown also prevented ceftriaxone from attenuating reinstatement and from upre

150 were isolated on selective media containing ceftriaxone from the wetland compared to feces, suggesti

151 16% to 27%, and there was a decrease in both ceftriaxone (from 39% to 33%) and azithromycin (change f

152 significantly more often in the doxycycline-ceftriaxone group (35%) than in either of the other two

153 p were numerically higher than those for the ceftriaxone group (for the clinically evaluable populati

154 ycycline group, and 86.5% in the doxycycline-ceftriaxone group (P > 0.2).

155 liary adverse events were more common in the ceftriaxone group than in the placebo group (gastrointes

156 l group and 178 (74%) of 240 patients in the ceftriaxone group were clinically cured at the test-of-c

157 Significantly more participants who received ceftriaxone had serious hepatobiliary serious adverse ev

158 this consideration and its lack of toxicity, ceftriaxone has potential to manipulate glutamate transm

159 The resistance to ceftriaxone has remained low, suggesting it is likely to

160 tended-spectrum cephalosporins--cefixime and ceftriaxone--have been recommended in the UK for treatme

161 failure, compared with 19 (16%) who received ceftriaxone (hazard ratio [HR] 1.04 [95% CI 0.55-1.98];

162 ns with high-level resistance to cefixime or ceftriaxone heralds the possible demise of beta-lactam a

163 , compared with four (7%) of 54 who received ceftriaxone (HR 0.24 [95% CI 0.08-0.73]; p=0.01).

164 treatment versus 15 (23%) of 65 who received ceftriaxone (HR 7.50 [95% CI 1.71-32.80]; p=0.01).

165 6, cefaclor in 82, and cefuroxime axetil and ceftriaxone in 22 subjects) were well tolerated.

166 Our data support the role of ceftriaxone in alleviating alcohol withdrawal and open a

167 ising stage 2 data, stage 3 of this trial of ceftriaxone in amyotrophic lateral sclerosis did not sho

168 amil should be regarded as an alternative to ceftriaxone in empirical treatment regimens for this pat

169 stage 3 (efficacy), participants assigned to ceftriaxone in stage 2 received 4 g ceftriaxone, partici

170 safety of ceftaroline fosamil compared with ceftriaxone in the treatment of Asian patients admitted

171 xacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.

172 When delivered to animals, the beta-lactam ceftriaxone increased both brain expression of GLT1 and

173 In addition, ceftriaxone increased glutamate uptake, a primary functi

174 ays disease onset and prolongs survival, and ceftriaxone increases EAAT2 activity.

175 Immunoblotting confirmed that the ceftriaxone-induced blockade of cocaine relapse was asso

176 cue-induced food seeking, arguing against a ceftriaxone-induced effect unique to extinction training

177 small interference RNA completely inhibited ceftriaxone-induced glutamate uptake activity in PHFA.

178 argeting antibiotics, such as vancomycin and ceftriaxone, inhibit the kinase activity of Stk1 and lea

179 Both piperacillin-tazobactam and ceftriaxone inhibited colonization by an enterococcal st

180 after each extinction session, rats received ceftriaxone (intraperitoneally), a beta-lactam antibioti

181 Taken together, our data indicate that ceftriaxone is a potent modulator of glutamate transport

182 ptional mechanism, and their coregulation by ceftriaxone is not mediated by physical interaction.

183 Ceftriaxone is recommended when parenteral antibiotic th

184 us pneumoniae with reduced susceptibility to ceftriaxone is reported increasingly, and alternatives a

185 Ceftriaxone is the foundation of currently recommended g

186 error, 13.0%), cefotaxime (m error, 21.2%), ceftriaxone (m error, 23.3%), tetracycline (M error, 11.

187 0.008 to 2 mug/ml); all were susceptible to ceftriaxone (median MIC, 0.015 mug/ml; range, 0.008 to 1

188 Our results reveal that the ceftriaxone-mediated attenuation of cue-induced cocaine

189 on of the EAAT2 promoter was responsible for ceftriaxone-mediated EAAT2 induction.

190 n NAc core, but not shell, would reverse the ceftriaxone-mediated effect.

191 Furthermore, ceftriaxone-mediated upregulation of surface GLT1 expres

192 etive criteria were proposed for cefotaxime, ceftriaxone, meropenem, azithromycin, and minocycline.

193 from 1,386 clinical isolates suggest that a ceftriaxone MIC cutoff of 8 mug/ml is an excellent predi

194 oline was generally 16-fold more active than ceftriaxone (MIC(50), 4 mug/mL; MIC(90), 4 mug/mL; 97.9%

195 microg/mL) and was 16-fold more active than ceftriaxone (MIC(90), 2 microg/mL).

196 spectively) and was 16-fold more active than ceftriaxone (MIC(90), 2 microg/mL).

197 azithromycin (MIC90s, < or =0.12 microg/ml), ceftriaxone (MIC90s, 0.5 microg/ml), and levofloxacin (M

198 ncentrations (MICs) >256 mug/mL and elevated ceftriaxone MICs (>/=0.125 mug/mL).

199 ad azithromycin MICs >16 microg/mL and 5 had ceftriaxone MICs = 0.125 microg/mL by agar dilution.

200 er of clinical microbiology laboratories use ceftriaxone MICs as a proxy means of identifying bacteri

201 he isolates showed reduced susceptibility to ceftriaxone (MICs, >or=16 microg/ml).

202 Isolates with ceftriaxone minimum inhibitory concentration >/= 1 micro

203 geal and rectal isolates, there were 10 with ceftriaxone minimum inhibitory concentration (MIC) >/=0.

204 Isolates with ceftriaxone minimum inhibitory concentrations >/=2 micro

205 Twelve of the 15 Salmonella isolates with ceftriaxone minimum inhibitory concentrations of 16 micr

206 In conclusion, Ceftriaxone modulated the expression of the glutamate tr

207 These findings suggest a mechanism for ceftriaxone modulation of glutamate transport and for it

208 After treatment with ceftriaxone mono- or dual therapy (with azithromycin or

209 (+/- 1.7), whereas in 13 cases treated with ceftriaxone monotherapy, the time to defervescence was 6

210 In the presence of ceftriaxone, neither system was able to recover Streptoc

211 These data indicate that ceftriaxone normalizes multiple aspects of glutamate hom

212 Ceftriaxone, one of the beta-lactam antibiotics, is a st

213 at at high concentration neither Inh2-B1 nor Ceftriaxone or Cefotaxime alone was able to inhibit the

214 as observed at a micromolar concentration of Ceftriaxone or Cefotaxime in the presence of Inh2-B1.

215 Participants received 2 g ceftriaxone or placebo twice daily through a central ven

216 icipants were randomly assigned (2:1) to 4 g ceftriaxone or placebo.

217 with or without a single intravenous dose of ceftriaxone, or 20 days of oral doxycycline.

218 or which the MIC of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >or=2 microg/ml or the MIC

219 For a ceftazidime, ceftriaxone, or cefotaxime MIC of > or =2 microg/ml, a d

220 l E. coli) tested susceptible to cefotaxime, ceftriaxone, or ceftazidime.

221 strain 536 and received 536_P1 intranasally, ceftriaxone, or control.

222 were treated with antibiotics (azithromycin, ceftriaxone, or doxycycline) for 30 consecutive days.

223 illin (P<0.0001), ampicillin (P = 0.01), and ceftriaxone (P = 0.006).

224 ity (9 of 50 [18%] oxacillin vs 3 of 74 [4%] ceftriaxone; P = .01).

225 igned to ceftriaxone in stage 2 received 4 g ceftriaxone, participants assigned to placebo in stage 2

226 ug use occurred during the 2-week open-label ceftriaxone phase, and no serious drug-related adverse e

227 rescribing practice in 2010 from cefixime to ceftriaxone plus azithromycin.

228 Ceftriaxone promoted colonization at doses at least 0.5

229 ation of GLT-1 expression in astrocytes with ceftriaxone protected CA1 neurons from forebrain ischemi

230 43 patients developed CDI within 30 days of ceftriaxone receipt, an incidence of 5.60 cases per 10 0

231 Furthermore, ceftriaxone reduced ethanol drinking, suggesting that EN

232 Rapidly emerging resistance against ceftriaxone requires urgent reevaluation of antibiotic r

233 Ceftriaxone resistance among S. pneumoniae was 2.1% (10.

234 Ceftriaxone resistance increased in blood isolates from

235 esistance and DCS; rates of azithromycin and ceftriaxone resistance were 0.6% and absent, respectivel

236 pyema; the emergence of multidrug, including ceftriaxone, resistant serotype 19A strains; and the nee

237 Ten (77%) of the 13 patients with ceftriaxone-resistant infections were aged 18 years or y

238 The ceftriaxone-resistant isolate from the child was indisti

239 Both ceftriaxone-resistant isolates were closely related to t

240 Both ceftriaxone-resistant isolates were resistant to 13 anti

241 Among 70 ceftriaxone-resistant pneumococcal isolates, all were in

242 plasmids and beta-lactamases to compare the ceftriaxone-resistant S. enterica serotype typhimurium f

243 Domestically acquired ceftriaxone-resistant Salmonella has emerged in the Unit

244 Nationally, the prevalence of ceftriaxone-resistant Salmonella increased from 0.5% in

245 Patients with ceftriaxone-resistant Salmonella infections between 1996

246 Ceftriaxone-resistant Salmonella infections have recentl

247 Most ceftriaxone-resistant Salmonella isolates had similar Am

248 The prevalence of ceftriaxone-resistant Salmonella was 0.1% (1 of 1326) in

249 analyzed the molecular characteristics of a ceftriaxone-resistant strain of Salmonella enterica sero

250 From 2012, we have observed an emergence of ceftriaxone-resistant strains also showing reduced susce

251 We also found that ceftriaxone restores glutamate reuptake and attenuates t

252 nd microdialysis to test the hypothesis that ceftriaxone restores the function of both GLT-1 and xCT

253 n that chronic treatment with the antibiotic ceftriaxone restores xCT and GLT-1 expression following

254 ecreased susceptibility to both cefixime and ceftriaxone rose between 2007 and 2010 but was more noti

255 In particular, ceftriaxone significantly decreases the growth rate of a

256 LOLA (as an add-on therapy to lactulose and ceftriaxone) significantly improves the grade of OHE ove

257 n, Streptococcus pneumoniae, vancomycin, and ceftriaxone, Streptococcus agalactiae, ampicillin, and c

258 y related gonococcal isolates with decreased ceftriaxone susceptibility and high-level azithromycin r

259 were interviewed and isolates with decreased ceftriaxone susceptibility were further characterized.

260 several of which also demonstrated decreased ceftriaxone susceptibility.

261 more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0.51 un

262 utamate transport in the accumbens core with ceftriaxone the capacity of acute stress to augment the

263 Resistance to ceftriaxone, the drug of choice for invasive salmonella

264 en percent of the isolates were resistant to ceftriaxone, the drug of choice for treating salmonellos

265 Except for the last trial with ceftriaxone, the fluoroquinolone gatifloxacin was associ

266 In cultures treated with ceftriaxone, the pH of the culture medium did not change

267 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93

268 Notably, all organisms were susceptible to ceftriaxone throughout the study period (2005-2014), and

269 CT and GLT-1 are essential to the ability of ceftriaxone to attenuate cue-induced reinstatement of co

270 June 2005 and 31 December 2010 who received ceftriaxone to determine whether the additional receipt

271 ctrophysiology to investigate the ability of ceftriaxone to normalize measures of synaptic plasticity

272 s were followed from first administration of ceftriaxone to occurrence of CDI or administrative closu

273 of both proteins in mediating the ability of ceftriaxone to prevent cue-induced reinstatement of coca

274 ine from 10 to 20 days or adding one dose of ceftriaxone to the beginning of a 10-day course of doxyc

275 By adding antibodies to antibiotic (ceftriaxone)-treated mice, we further reduce the bacteri

276 PCR for up to 56 days in aliquots from both ceftriaxone-treated and untreated cultures.

277 We found that 5 d of ceftriaxone treatment following cocaine self-administrat

278 the ceftaroline treatment group than in the ceftriaxone treatment group (59 of 69 [85.5%] vs 48 of 7

279 Similarly, ceftriaxone treatment prevented stress-induced potentiat

280 In addition, although ceftriaxone treatment resulted in a reduction in the qua

281 Finally, ceftriaxone treatment was associated with lasting upregu

282 nt, noncultivable Borrelia burgdorferi after ceftriaxone treatment was examined.

283 In the absence of cocaine or ceftriaxone treatment, xCT knockdown in the NAc increase

284 We found a significant reduction in ceftriaxone use with a concomitant increase in targeted

285 In this comparison of ceftriaxone versus oxacillin for MSSA osteoarticular inf

286 MSSA osteoarticular infections treated with ceftriaxone versus oxacillin.

287 ession with oral antibiotics (31 of 74 [42%] ceftriaxone vs 25 of 50 [50%] oxacillin; P = .4).

288 illin; P = .7) and >6 months (43 of 56 [77%] ceftriaxone vs 26 of 32 [81%] oxacillin; P = .6).

289 ss was similar at 3-6 months (50 of 60 [83%] ceftriaxone vs 32 of 37 [86%] oxacillin; P = .7) and >6

290 bo group (gastrointestinal, 245 of 340 [72%] ceftriaxone vs 97 of 173 [56%] placebo, p=0.0004; hepato

291 The outcome after 14-day treatment with ceftriaxone was favorable in 87.8% of patients.

292 rapy of intravenous daptomycin, rifampin and ceftriaxone was initiated.

293 Ceftriaxone was neuroprotective in vitro when used in mo

294 Although no resistance to ciprofloxacin or ceftriaxone was observed, 20 isolates (7%) were nalidixi

295 Additionally, under our study conditions, ceftriaxone was suboptimum in a high proportion of patie

296 d of care treatment (including lactulose and ceftriaxone) was given in both groups.

297 administration of the beta-lactam antibiotic ceftriaxone, which promotes synaptic glutamate clearance

298 Multidrug resistance, including to ceftriaxone, will pose further difficulty in management

299 ducibility of broth microdilution testing of ceftriaxone with N. cyriacigeorgica and N. wallacei, tig

300 Ceftriaxone with or without a macrolide antibiotic is a